BioVie Achieved Alignment With The FDA On Its Upcoming SUNRISE-PD Trial In Parkinson's Disease. As A Result, The Company Is Conducting Trial Start-up Activities With A View To Initiate Patient Screening In Q4 2024
Portfolio Pulse from Benzinga Newsdesk
BioVie has aligned with the FDA on its upcoming SUNRISE-PD trial for Parkinson's disease, focusing on the effects of bezisterim (NE3107) on motor and non-motor symptoms in approximately 60 patients. The company plans to start patient screening in Q4 2024.
August 08, 2024 | 10:09 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioVie has received FDA alignment for its SUNRISE-PD trial, which will evaluate bezisterim (NE3107) in Parkinson's disease patients. The company is preparing to start patient screening in Q4 2024.
The FDA alignment is a significant regulatory milestone for BioVie, potentially boosting investor confidence. The initiation of patient screening in Q4 2024 indicates progress in their clinical development pipeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100